XETRA - Delayed Quote • EUR Becton, Dickinson and Company (BOX.DE) Follow Compare 228.00 0.00 (0.00%) As of 11:40:02 AM GMT+1. Market Open. All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations New ASCCP Guidelines Include More Precise Method of Cervical Cancer Screening BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that the BD Onclarity™ HPV Assay has officially been added to the American Society for Colposcopy and Cervical Pathology (ASCCP) Enduring Risk-Based Management Guidelines, due to its ability to individually identify more high-risk types of HPV. Becton Dickinson (NYSE:BDX) Seems To Use Debt Quite Sensibly Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's... The Forgotten Four Bottom Fishing for recovering fallen large caps which are showing improvement BD Names Pamela Spikner as Chief Accounting Officer and Controller BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that Pamela Spikner has been named senior vice president, chief accounting officer and controller, effective January 20. Here's Why Becton Dickinson (BDX) is a Strong Growth Stock Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. New Survey Finds Women Are Skipping Their OB/GYN Exams, Increasing Risks for Cervical Cancer BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the results of a new survey, revealing that 72% of women in the United States have delayed having a gynecology visit, with many highlighting the need for greater convenience, comfort and ease for this critical cervical cancer screening process. BD To Host Virtual 2025 Annual Meeting of Shareholders BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will host its virtual 2025 Annual Meeting of Shareholders (the "Annual Meeting") on Tuesday, January 28, 2025, at 1:00 p.m. (ET). Will Becton Dickinson (BDX) Beat Estimates Again in Its Next Earnings Report? Becton Dickinson (BDX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report. Here's Why You Should Retain BDX Stock in Your Portfolio for Now BD's robust product portfolio and a few strategic deals raise optimism about the stock. However, stiff competition and macroeconomic volatility are concerns. An Intrinsic Calculation For Becton, Dickinson and Company (NYSE:BDX) Suggests It's 22% Undervalued Key Insights Becton Dickinson's estimated fair value is US$294 based on 2 Stage Free Cash Flow to Equity Becton... Becton Dickinson (BDX) is a Top-Ranked Value Stock: Should You Buy? Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. BDX vs. MMSI: Which Stock Is the Better Value Option? BDX vs. MMSI: Which Stock Is the Better Value Option? 5 Top AI-in-MedTech Stocks for Big Gains in 2025: MDT, BSX & More Here we discuss five medical stocks - MDT, BSX, BDX, GEHC and TEM - incorporating AI in their workflows. These are likely to gain in 2025 as AI helps cut costs and improve patient care. The past five years for Becton Dickinson (NYSE:BDX) investors has not been profitable The main aim of stock picking is to find the market-beating stocks. But even the best stock picker will only win with... Why Becton Dickinson (BDX) is a Top Growth Stock for the Long-Term The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. BDX Stock Down Despite New Expansion to Boost Fingertip Blood Testing The blood testing process integrating BD's MiniDraw System with Babson's BetterWay technologies is likely to lower common barriers to testing and improve patient outcomes. Here's Why Becton Dickinson (BDX) is a Strong Value Stock The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. BD and Babson expand fingertip blood testing across US health systems The system is designed to be less invasive and can be performed by any trained healthcare worker. Why Becton Dickinson (BDX) is a Top Momentum Stock for the Long-Term The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. BD and Babson Diagnostics Launch Innovative Fingertip Blood Testing to Health Care Organizations BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Babson Diagnostics, a science-first health care technology company, today announced an expansion of fingertip blood collection and testing technologies for use by U.S. health systems and other large provider networks in settings like urgent cares, doctor offices and other ambulatory care settings. Performance Overview Trailing total returns as of 1/15/2025, which may include dividends or other distributions. Benchmark is S&P 500 Return BOX.DE S&P 500 YTD +3.92% -1.08% 1-Year +8.00% +22.14% 3-Year +7.00% +25.31%